Recurrent Sporadic Parathyroid Carcinoma in a 29-Year-Old Filipino Female Presenting with Primary Hyperparathyroidism
A Case Report and Literature Review
DOI:
https://doi.org/10.21141/PJP.2026.583Keywords:
parathyroid carcinoma, tumor recurrence, hyperparathyroidism, bone pains, pathologic fractures, case report, PhilippinesAbstract
Parathyroid carcinoma is a rare endocrine malignancy with an indolent course but a high risk of recurrence. Diagnosis remains challenging, requiring integration of clinical, biochemical, radiologic, and histopathologic findings. We report a young patient presenting with primary hyperparathyroidism complicated by multiple pathologic fractures and chronic renal failure. Despite initial surgical and medical management, late aggressive recurrence occurred, resulting in significant systemic complications. This case highlights the need for vigilant long-term surveillance and improved diagnostic and therapeutic strategies.
Downloads
References
Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109(9):1736-41. https://pubmed.ncbi.nlm.nih.gov/17372919 https://doi.org/10.1002/cncr.22599
Ullah A, Khan J, Waheed A, et al. Parathyroid carcinoma: incidence, survival analysis, and management: a study from the SEER database and insights into future therapeutic perspectives. Cancers (Basel). 2022;14(6):1436. https://pubmed.ncbi.nlm.nih.gov/35326576 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946517 https://doi.org/10.3390/cancers14061426
Zelano L, Locantore P, Rota CA, et al. Parathyroid carcinoma all-in-one, a rare life-threatening case with multiple systemic manifestations: case report and review of the literature. Front Endocrinol (Lausanne). 2022;13:881225. https://pubmed.ncbi.nlm.nih.gov/35872978 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300921 https://doi.org/10.3389/fendo.2022.881225
Cardoso L, Stevenson M, Thakker RV. Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. Hum Mutat. 2017;38(12):1621-48. https://pubmed.ncbi.nlm.nih.gov/28881068 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698716 https://doi.org/10.1002/humu.23337
Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP. Parathyroid carcinoma. J Bone Miner Res. 2008;23(12):1869-80. https://pubmed.ncbi.nlm.nih.gov/19016595 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276344 https://doi.org/10.1359/jbmr.081018
Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):485-93. https://pubmed.ncbi.nlm.nih.gov/11157996 https://doi.org/10.1210/jcem.86.2.7207
American Joint Committee on Cancer. AJCC cancer staging manual, 8th ed. Springer; 2017.
Fingeret AL. Contemporary evaluation and management of parathyroid carcinoma. JCO Oncol Pract. 2021;17(1):17-21. https://pubmed.ncbi.nlm.nih.gov/32040373 https://doi.org/10.1200/JOP.19.00540
Hu Y, Liao Q, Cao S, Gao X, Zhao Y. Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis. Endocrine. 2016;54(3):612-9. https://pubmed.ncbi.nlm.nih.gov/27250989 https://doi.org/10.1007/s12020-016-0997-3
Perrier ND, Arnold A, Costa-Guda J, et al. Hereditary endocrine tumors: current state-of-the-art and research opportunities: new and future perspectives for parathyroid carcinoma. Endocr Relat Cancer. 2020;27(8):T53-63. https://pubmed.ncbi.nlm.nih.gov/32449693 https://doi.org/10.1530/ERC-20-0018
World Health Organization. WHO classification of tumours: endocrine and neuroendocrine tumours, 5th ed. IARC Press; 2017.
Uljanovs R, Sinkarevs S, Strumfs B, Vidusa L, Merkurjeva K, Strumfa I. Immunohistochemical profile of parathyroid tumors: a comprehensive review. Int J Mol Sci. 2022;23(13):6981. https://pubmed.ncbi.nlm.nih.gov/35805976 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266566 https://doi.org/10.3390/ijms23136981
Truran PP, Johnson SJ, Bliss RD, Lennard TW, Aspinall SR. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 2014;38(11):2845-54. https://pubmed.ncbi.nlm.nih.gov/25002250 https://doi.org/10.1007/s00268-014-2700-2
Pyo JS, Cho WJ. Diagnostic and prognostic implications of parafibromin immunohistochemistry in parathyroid carcinoma. Biosci Rep. 2019;39(4):BSR20181778. https://pubmed.ncbi.nlm.nih.gov/30926677 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488858 https://doi.org/10.1042/BSR20181778
Machado NN, Wilhelm SM. Parathyroid cancer: a review. Cancers (Basel). 2019;11(11):1676. https://pubmed.ncbi.nlm.nih.gov/31661917 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896123 https://doi.org/10.3390/cancers11111676
Cui M, Hu Y, Bi Y, et al. Preliminary exploration of potential molecular therapeutic targets in recurrent and metastatic parathyroid carcinomas. Int J Cancer. 2019;144(3):525-32. https://pubmed.ncbi.nlm.nih.gov/30362515 https://doi.org/10.1002/ijc.31948
Ippolito G, Palazzo FF, Sebag F, De Micco C, Henry JF. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg. 2007;94(5):566-70. https://pubmed.ncbi.nlm.nih.gov/17380564 https://doi.org/10.1002/bjs.5570
Long KL, Sippel RS. Current and future treatments for parathyroid carcinoma. Int J Endocr Oncol. 2018;5(1):IJE06. https://doi.org/10.2217/ije-2017-0011
Marini F, Giusti F, Palmini G, et al. Parathyroid carcinoma: update on pathogenesis and therapy. Endocrines. 2023;4(1):205-35. https://doi.org/10.3390/endocrines4010013
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Eldimson Bermudo, Jose Vicente Borja, Al-Zamzam Abubakar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
@philippinepathologyjournal